{
    "ticker": "KIDS",
    "name": "Zynerba Pharmaceuticals, Inc.",
    "description": "Zynerba Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cannabinoid-based medicines for patients with debilitating neuropsychiatric conditions. Founded in 2007 and headquartered in Devon, Pennsylvania, Zynerba aims to leverage its proprietary transdermal delivery technology to create formulations that can administer cannabinoids effectively and safely. The company\u2019s lead product candidate, Zygel, is designed for the treatment of rare neurodevelopmental conditions such as Fragile X syndrome and autism spectrum disorder. With a strong emphasis on research and development, Zynerba is committed to advancing the understanding of cannabinoid therapies and expanding access to these treatments for patients in need. The company seeks to set a new standard of care in the management of symptoms associated with these conditions, focusing on the safety and efficacy of its products through rigorous clinical trials. Zynerba\u2019s mission is to improve the quality of life for patients and their families by providing innovative therapeutic options that address unmet medical needs in the field of neuropsychiatry.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "Devon, Pennsylvania, USA",
    "founded": "2007",
    "website": "https://www.zynerba.com",
    "ceo": "Armando Anido",
    "social_media": {
        "twitter": "https://twitter.com/ZynerbaPharma",
        "linkedin": "https://www.linkedin.com/company/zynerba-pharmaceuticals/"
    },
    "investor_relations": "https://investor.zynerba.com",
    "key_executives": [
        {
            "name": "Armando Anido",
            "position": "CEO"
        },
        {
            "name": "Raghav Mehta",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cannabinoid-based Therapies",
            "products": [
                "Zygel"
            ]
        }
    ],
    "seo": {
        "meta_title": "Zynerba Pharmaceuticals, Inc. | Innovative Cannabinoid-based Medicines",
        "meta_description": "Explore Zynerba Pharmaceuticals, Inc., a leader in cannabinoid-based therapies for neuropsychiatric conditions. Learn about their groundbreaking product Zygel and commitment to patient care.",
        "keywords": [
            "Zynerba",
            "Cannabinoids",
            "Pharmaceuticals",
            "Neuropsychiatry",
            "Zygel",
            "Fragile X syndrome",
            "Autism"
        ]
    },
    "faq": [
        {
            "question": "What is Zynerba Pharmaceuticals known for?",
            "answer": "Zynerba Pharmaceuticals is known for developing cannabinoid-based medicines for neuropsychiatric conditions."
        },
        {
            "question": "Who is the CEO of Zynerba Pharmaceuticals?",
            "answer": "Armando Anido is the CEO of Zynerba Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Zynerba Pharmaceuticals headquartered?",
            "answer": "Zynerba Pharmaceuticals is headquartered in Devon, Pennsylvania, USA."
        },
        {
            "question": "What is Zynerba's lead product?",
            "answer": "Zynerba's lead product candidate is Zygel, aimed at treating Fragile X syndrome and autism spectrum disorder."
        },
        {
            "question": "When was Zynerba Pharmaceuticals founded?",
            "answer": "Zynerba Pharmaceuticals was founded in 2007."
        }
    ],
    "competitors": [
        "GWPH",
        "AXDX",
        "INVE"
    ],
    "related_stocks": [
        "VRTX",
        "AMGN",
        "BMY",
        "REGN"
    ]
}